255 related articles for article (PubMed ID: 38191502)
1. Exploring public interest in gut microbiome dysbiosis, NAFLD, and probiotics using Google Trends.
Pezzino S; Sofia M; Mazzone C; Litrico G; Agosta M; La Greca G; Latteri S
Sci Rep; 2024 Jan; 14(1):799. PubMed ID: 38191502
[TBL] [Abstract][Full Text] [Related]
2. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.
Khan A; Ding Z; Ishaq M; Bacha AS; Khan I; Hanif A; Li W; Guo X
Int J Biol Sci; 2021; 17(3):818-833. PubMed ID: 33767591
[TBL] [Abstract][Full Text] [Related]
3. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
Safari Z; Gérard P
Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
[TBL] [Abstract][Full Text] [Related]
4. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
Cho MS; Kim SY; Suk KT; Kim BY
J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
[TBL] [Abstract][Full Text] [Related]
5. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
9. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
Bakhshimoghaddam F; Alizadeh M
Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiome and non-alcoholic fatty liver disease.
Purohit A; Alam MJ; Kandiyal B; Shalimar ; Das B; Banerjee SK
Prog Mol Biol Transl Sci; 2022; 191(1):187-206. PubMed ID: 36270678
[TBL] [Abstract][Full Text] [Related]
11. The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease.
Jacob JS; Ahmed A; Cholankeril G
Curr Opin Infect Dis; 2021 Oct; 34(5):477-482. PubMed ID: 34267042
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota and non-alcoholic fatty liver disease.
Gkolfakis P; Dimitriadis G; Triantafyllou K
Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
[TBL] [Abstract][Full Text] [Related]
13. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease.
Yang YJ; Ni YH
J Formos Med Assoc; 2019 Mar; 118 Suppl 1():S55-S61. PubMed ID: 30509561
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Probiotics (MCP
Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
[TBL] [Abstract][Full Text] [Related]
16. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.
Fang J; Yu CH; Li XJ; Yao JM; Fang ZY; Yoon SH; Yu WY
Front Cell Infect Microbiol; 2022; 12():997018. PubMed ID: 36425787
[TBL] [Abstract][Full Text] [Related]
17. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.
Jennison E; Byrne CD
Clin Mol Hepatol; 2021 Jan; 27(1):22-43. PubMed ID: 33291863
[TBL] [Abstract][Full Text] [Related]
18. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
[TBL] [Abstract][Full Text] [Related]
19. Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date.
Moszak M; Szulińska M; Walczak-Gałęzewska M; Bogdański P
Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33567710
[TBL] [Abstract][Full Text] [Related]
20. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
